Legal Status: | Investigational |
Iupac Name: | (9Z,12Z)-2-Hydroxyoctadeca-9,12-dienoic acid |
Cas Number: | 57818-44-7 |
Pubchem: | 21158511 |
Unii: | 0DE74TJ7EZ |
Synonyms: | α-Hydroxylinoleic acid; 2-Hydroxylinoleic acid; ABTL-0812 |
C: | 18 |
H: | 32 |
O: | 3 |
Smiles: | CCCCC/C=C\C/C=C\CCCCCCC(C(=O)O)O |
ABTL0812 (α-hydroxylinoleic acid) is a small-molecule, experimental cancer drug being developed by Ability Pharmaceuticals.[1]
In 2015, Ability announced that it had received orphan drug designation (ODD) for pediatric cancer neuroblastoma from the European Medical Agency (EMA) and the US Food and Drug Administration (FDA).[1] Also in 2016 a preclinical study confirmed that ABTL0812 was well tolerated.[2] In December 2016 the company announced ODD for the treatment of pancreatic cancer.[1]
One mechanism of action is the activation of the PPAR receptors and the TRIB3 gene, leading to inhibition of the Akt/mTOR pathway. This pathway is excessively activated in most human cancers, supporting tumor growth. It is a principal target of various new anti-tumour drugs. Tumor cells are killed viva autophagy, rather than apoptosis.[3]
ABTL0812 activates the PPAR receptors, inducing TRIB3 over-expression. TRIB3 binds to the Akt oncogene and inhibits the Akt/mTOR axis.[4]
ABTL0812 showed efficacy in Phase I clinical trials in patients with advanced cancer, with low toxicity and high tolerability.[4]